Citrine SAL Investment & Holdings Ltd. (Citrine Investment Funds)

www.citrineinvest.com

Investment Company

Tech Verticals Preferences

AgriTech, Biotechnology, Blockchain, Cleantech, Cyber Security, Data Analytics, Digital Health, Energy Tech, FoodTech, Green Energy, IoT, Media, Medical Cannabis, Medical Devices, MedTech, Security

General Data

Established	2015
Current Active Portfolio Companies:	6
Reg. Number:	abCDe

DESCRIPTION

Citrine Technology Investment funds, from Wealthstone Holdings Group, provides a full array of financial and business services, including M&As as well as Public & Private Placements, helping
companies realize their true market potential. It offers a unique platform presenting various models of limited partnerships & flexible investment periods to help investors meet their investment needs and minimize risk.
Citrine focuses on high-profile technology companies that have a good potential for international market breakthroughs & substantial value leap.

Citrine private equity funds include:
Citrine Biotech - Specializing in medical devices and health products, mobile health, wellness products and supplements, improving quality of life and personalized medicine.
Citrine Food Tech & Medical Cannabis - specializes in unique solutions for the global, meteorically growing food tech and medical cannabis markets.
Citrine Hi-tech - Specializes in innovative clean-tech/green energy solutions, cyber technology, Media, IoT, HW & SW.

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
		Wealthstone Holdings Ltd.
E1C14620-9923-E911-80FD-0050569A1018	Investment Arm	Citrine SAL Investment & Holdings Ltd. (Citrine Investment Funds)	Wealthstone Holdings Ltd.
E7AB4550-BDC9-F011-B81A-00505695CD29	Subsidiary	SkyTech Orion Ltd.	Citrine SAL Investment & Holdings Ltd. (Citrine Investment Funds)

CONTACT INFO

Expand / Collapse All

Main Address: Ramat Gan, Israel

Address	2 Zeev Jabutinsky Rd. Amot Atrium Tower
City	Ramat Gan
Country	Israel
Zip	5250501

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Ms. Ora Elharar-Soffer	Founding General Partner
Mr. Yaron Pitaru	Founding General Partner	JTI (Director)
Mr. Ilan Ben-Ishay	Partner & Strategic Advisor

	Acquisitions made by Citrine Investment Funds

Acquired Company	Sector	Date	Amount	Remarks
abC Defghij	Biomed...	Jan. 01, 2020	abCDe

Preferences

Stage Preferences

Initial Revenues,R&D,Seed

SECTOR SEGMENTATION (By Number Of Companies)

Agritech

25%

Biomed

25%

Digital Health

25%

Medical Devices

25%

	PORTFOLIO COMPANIES

Current Portfolio Companies (6)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

Dario

Dig. Health

PIPE

31/07/2020

N/A

$28.6m

Grow Nation

N/A

Investment in Fund

01/01/2019

N/A

iBOT

Agri

First Round	21/11/2023	N/A	N/A	Acquired 19% of the equity of iBOT with an option to obtain an additional 32%.
Seed	01/03/2019	N/A	N/A

ICB

ICB - Israel China Biotechnology Investments Ltd. - specializes in investing and developing Israeli biomedical companies with potential in the Chinese market. It focuses on high-tech projects investment in Israel and committed to become China-Israel biomedical field’s “Alibaba”. ICB has a holey owned subsidiary - BSP Medical and its engineering facilities in Israel and prominent partners in China- CIB company, that fully operates in the the Municipal Government High-Tech Zone in Changsha, China.

N/A

Investment in Fund

01/06/2018

N/A

SpinCare

Second Round	31/01/2022	N/A	$3.5m
First Round	15/06/2020	N/A	$2.2m

Tikun Olam Cannbit

Cannbit is involved with the growth of medical cannabis, and intends to operate in the field of production, including the establishment of a plant and marketing of cannabis products for medical use.
Cannbit are building the best Cannabis company this side of the pond by creating a unique and visionary Cannabis Ecosystem.

A team of researchers from the Hebrew University have done research on molecules that have been found to be effective in cancer treatment. That is, in practice, this is not a drug produced from the cannabis plant, but a chemical molecule that simulates cannabinoid activity. This gave researchers initial indications in the lab that it may be effective in treating melanoma (skin cancer), and neuroblastoma and glioblastoma (types of brain cancer) - and lead to withdrawal.

Biomed

PIPE

22/12/2019

N/A

$7.6m

Exits (2)

Company Name	Exit Type	Date Announced	Amount	Remarks
abC Defghij	Acquired	01/09/2023	abCDe	Share swap reverse merger deal; Valuation NIS 143m
abC Defghij	Acquired	01/01/2020	abCDe

Historic Portfolio (4)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

BioCep

Suspendeed Operations

Biomed

Third Round

01/06/2018

N/A

ImProDia

Suspendeed Operations

Biomed

First Round

01/06/2019

N/A

Nicast

Ceased to Operate

Third Round

01/03/2019

N/A

WellBe

Ceased to Operate

CO SW

Seed

01/12/2015

N/A

Last Updated:	abCDe
IVC Number:	abCDe

Citrine SAL Investment & Holdings Ltd. (​Citrine Investment Funds)

Citrine SAL Investment & Holdings Ltd. (Citrine Investment Funds)